Chemed/$CHE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Chemed
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Ticker
$CHE
Sector
Primary listing
NYSE
Employees
15,695
Headquarters
Website
Chemed Metrics
BasicAdvanced
$6.8B
24.57
$18.95
0.43
$2.10
0.52%
Price and volume
Market cap
$6.8B
Beta
0.43
52-week high
$623.61
52-week low
$408.42
Average daily volume
197K
Dividend rate
$2.10
Financial strength
Current ratio
1.353
Quick ratio
1.182
Long term debt to equity
9.238
Total debt to equity
13.14
Dividend payout ratio (TTM)
11.01%
Interest coverage (TTM)
206.74%
Profitability
EBITDA (TTM)
417.295
Gross margin (TTM)
32.88%
Net profit margin (TTM)
11.02%
Operating margin (TTM)
14.12%
Effective tax rate (TTM)
24.74%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
13.16%
Return on equity (TTM)
24.11%
Valuation
Price to earnings (TTM)
24.566
Price to revenue (TTM)
2.688
Price to book
6.22
Price to tangible book (TTM)
20.63
Price to free cash flow (TTM)
18.875
Free cash flow yield (TTM)
5.30%
Free cash flow per share (TTM)
24.665
Dividend yield (TTM)
0.45%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
6.45%
Earnings per share change (TTM)
-4.24%
3-year revenue growth (CAGR)
5.92%
10-year revenue growth (CAGR)
5.20%
3-year earnings per share growth (CAGR)
3.21%
10-year earnings per share growth (CAGR)
11.61%
3-year dividend per share growth (CAGR)
-30.04%
10-year dividend per share growth (CAGR)
-5.71%
What the Analysts think about Chemed
Analyst ratings (Buy, Hold, Sell) for Chemed stock.
Bulls say / Bears say
VITAS net patient revenue increased 5.8% to $396.2 million, driven by a 6.1% rise in days-of-care and a 4.2% increase in Medicare reimbursement rates, reflecting strong demand for end-of-life services (BusinessWire)
Total revenue climbed 3.8% to $618.8 million, marking the company’s tenth straight quarter of year-over-year revenue growth across its main businesses (BusinessWire)
Chemed closed Q2 2025 with $249.9 million in cash and zero debt, keeping a strong balance sheet to support growth plans and shareholder returns (SEC.gov)
GAAP diluted EPS dropped 23.2% to $3.57 in Q2, impacted by Medicare cap issues and increased operating costs at VITAS (BusinessWire)
Roto-Rooter's adjusted EBITDA fell 18.7% to $48.6 million, underlining margin pressure from higher digital marketing and labor expenses (BusinessWire)
VITAS’ adjusted EBITDA margin narrowed by 163 basis points to 16.2%, indicating rising cost pressures and an increasingly unfavorable mix in hospice care (BusinessWire)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
Chemed Financial Performance
Revenues and expenses
Chemed Earnings Performance
Company profitability
Chemed News
AllArticlesVideos
Chemed To Report Third-Quarter 2025 Earnings October 28, Related Conference Call To Be Held On October 29
Business Wire4 weeks ago
Chemed Corporation to Present at the Jefferies 2025 Healthcare Services Conference
Business Wire1 month ago
3 Recession-Ready Stocks That Thrive When the Economy Sputters
MarketBeat1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Chemed stock?
Chemed (CHE) has a market cap of $6.8B as of October 31, 2025.
What is the P/E ratio for Chemed stock?
The price to earnings (P/E) ratio for Chemed (CHE) stock is 24.57 as of October 31, 2025.
Does Chemed stock pay dividends?
Yes, the Chemed (CHE) stock pays dividends to shareholders. As of October 31, 2025, the dividend rate is $2.1 and the yield is 0.52%. Chemed has a payout ratio of 11.01% on a trailing twelve-month basis.
When is the next Chemed dividend payment date?
The next Chemed (CHE) dividend payment date is unconfirmed.
What is the beta indicator for Chemed?
Chemed (CHE) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.